Dashenlin Pharmaceutical Group Co., Ltd. 2026 First Extraordinary General Meeting Resolution Announcement

Stock Code: 603233 Stock Abbreviation: Dasenlin Announcement No.: 2026-011

Dasenlin Pharmaceutical Group Co., Ltd. 2026 First Extraordinary General Meeting of Shareholders Resolution Announcement

The board of directors of this company and all directors hereby warrant that there are no false statements, misleading representations, or material omissions in the contents of this announcement, and assume legal responsibility for the truthfulness, accuracy, and completeness of its contents.

Key Matters to Note:

● Whether any resolutions were vetoed at this meeting: None

I. Convening and Attendance of the Meeting

(1) Time of the General Meeting of Shareholders: March 30, 2026

(2) Location of the General Meeting of Shareholders: Conference Room, 4th Floor, Dasenlin Group Comprehensive Building, No. 410 Longxi Avenue, Liwan District, Guangzhou

(3) Shareholding information of the ordinary shareholders attending the meeting and the preferred shareholders restoring voting rights, and their shareholdings:

■

(4) Whether the voting method complies with the provisions of the Company Law and the Articles of Association, and the meeting chair situation, etc.

This meeting was convened by the board of directors of the company. After being nominated by more than half of the directors, the meeting was chaired by Director Guoqiang Ke. The meeting was held and voted on using both on-site voting and online voting. The convening and holding of the meeting comply with the relevant provisions of the Company Law, the Rules for General Meetings of Listed Companies, and the Articles of Association, etc.

(5) Attendance by the company’s directors and the secretary of the board of directors

1. There are 8 directors in office, and 8 attended;

2. Board secretary Guangzhi Peng attended this meeting.

II. Deliberation on Proposals

(1) Non-cumulative voting proposals

1. Proposal name: Proposal on Amending the Articles of Association and Its Appendices

Voting result: Passed

Voting situation:

■

2. Proposal name: Proposal on Extending the Business of Controlling Subsidiary Tianshen Health to Commercial Insurance and Professional Pharmacies

Voting result: Passed

Voting situation:

■

(2) Voting results of cumulative voting proposals

3. Proposal on Electing the Non-Independent Directors of the Fifth Session of the Board of Directors of the Company

■

4. Proposal on Electing the Independent Directors of the Fifth Session of the Board of Directors of the Company

■

(3) For major matters, voting situation of shareholders holding less than 5%

■

(4) Explanations regarding the relevant matters concerning the voting on the proposals

Proposal 1 is a special resolution matter of the general meeting of shareholders. It was approved with the consent of more than two-thirds of the voting rights held by the shareholders attending this general meeting and their proxies. In Proposal 2, related shareholders have fulfilled their obligation to abstain from voting. All proposals considered at this meeting have been approved.

III. Legal Counsel’s Witnessing Information

1. Law firm witnessing this general meeting: King & Wood Mallesons (Guangzhou) Law Firm

Lawyers: Xiaoguang Liu, Xiaodong Zi

2. Legal counsel’s conclusion:

Our attorneys believe that the procedures for convening and holding this general meeting of shareholders of the company comply with the provisions of relevant laws and administrative regulations such as the Company Law and the Securities Law, as well as the Rules for General Meetings of Listed Companies and the Articles of Association; the qualifications of the persons attending this general meeting and the convener are lawful and valid; the voting procedures and voting results of this general meeting are lawful and valid.

Announcement is hereby given.

Board of Directors of Dasenlin Pharmaceutical Group Co., Ltd.

March 31, 2026

大量资讯、精准解读，尽在新浪财经APP